Elixir
Made in America
I still have a bad taste in my mouth over them (UHC) letting scammers have every datum of info I ever gave them, right down to my SS# and the first four digits of a high value bank account.
Medical news
- Thread starter brewer
- Start date
brewer
don't sniff my butt
I question the timing of this considering the events in December. Does a CEO have to be killed these days for change? Unfortunately some will say yes. Better question, will this affect the trial and sentencing?
brewer
don't sniff my butt
Ectopic Pregnancy Deaths Have Nearly Doubled. It’s Worse in States With Abortion Bans.
While chaos and access issues at hospitals during the COVID-19 pandemic likely contributed to at least some of the deaths, the surge has persisted, raising serious questions about the role of the most significant disruption to maternal healthcare in the years since: state restrictions on abortion.
www.propublica.org
While chaos and access issues at hospitals during the COVID-19 pandemic likely contributed to at least some of the deaths, the surge has persisted, raising serious questions about the role of the most significant disruption to maternal healthcare in the years since: state restrictions on abortion.
Ectopic Pregnancy Deaths Have Nearly Doubled. It’s Worse in States With Abortion Bans.
With prompt and appropriate medical care, experts say, people shouldn’t die from an ectopic pregnancy. Women in Texas and Oklahoma have sued over delays in care, which, coupled with our new analysis, raises questions about the role of abortion bans.
www.propublica.org
brewer
don't sniff my butt
Scientists revive a powerful antibiotic that superbugs had defeated
Scientists have found a way to revive vancomycin, a powerful antibiotic that some dangerous bacteria have learned to resist. Instead of creating an entirely new drug, researchers paired vancomycin with a small molecule called pghi-4, which blocks a bacterial enzyme linked to resistance. The combination restored the antibiotic’s ability to kill drug-resistant E. faecium, raising hopes that similar chemical helpers could rescue other failing medicines.
Scientists have found a way to revive vancomycin, a powerful antibiotic that some dangerous bacteria have learned to resist. Instead of creating an entirely new drug, researchers paired vancomycin with a small molecule called pghi-4, which blocks a bacterial enzyme linked to resistance. The combination restored the antibiotic’s ability to kill drug-resistant E. faecium, raising hopes that similar chemical helpers could rescue other failing medicines.
Scientists revive a powerful antibiotic that superbugs had defeated
Scientists have found a way to revive vancomycin, a powerful antibiotic that some dangerous bacteria have learned to resist. Instead of creating an entirely new drug, researchers paired vancomycin with a small molecule called pghi-4, which blocks a bacterial enzyme linked to resistance. The...
www.sciencedaily.com
bilby
Fair dinkum thinkum
- Joined
- Mar 6, 2007
- Messages
- 44,087
- Gender
- He/Him
- Basic Beliefs
- Strong Atheist
Clavulanic Acid plays a similar role in blocking resistance to Amoxycillin. It's a neat trick, but the bacteria will win in the end.
The bacteria always win in the end.
brewer
don't sniff my butt
Not only amoxicillin, the entire penicillin class. There are other beta-lactamase inhibitors also. As far as I know pghi-4 only works with vancomycin. No clue if it works with other glycopeptide antibiotics.
brewer
don't sniff my butt
Never-Screened Cervical Cancer Rates Climb Among US Women
Nearly 1 in 3 women aged 21 to 29 years had never been screened for cervical cancer by 2023, up from roughly 1 in 8 in 2005, according to a new research letter published in JAMA Network Open.1 The study found the share of never-screened women aged 30 to 65 years also grew over the same period, reaching nearly 1 in 7.
Drawing on 9 cycles of the National Health Interview Survey (NHIS) conducted between 2005 and 2023, researchers found the proportion of women aged 21 to 29 years who reported never being screened for cervical cancer rose from 12.5% (3.5 million women) to 31.9% (6.2 million women), an average annual percentage change (AAPC) of 5.2% (95% CI, 4.3%-7.5%). The increase accelerated sharply after 2010, climbing at an annual rate of 7.9% (95% CI, 6.0%-14.4%) through 2023. Among women aged 30 to 65 years, never-screening rose from 5.3% (4.3 million) to 14.8% (9.2 million), an AAPC of 6.8% (95% CI, 3.1%-12.0%).
Additionally, human papillomavirus (HPV) vaccination uptake among women aged 21 to 29 years climbed from 5.7% in 2008 to 54.0% in 2019 but remains incomplete. The study authors noted that nearly 8 million women in this age group remain unvaccinated, and almost a third of them have also never been screened for cervical cancer.
Nearly 1 in 3 women aged 21 to 29 years had never been screened for cervical cancer by 2023, up from roughly 1 in 8 in 2005, according to a new research letter published in JAMA Network Open.1 The study found the share of never-screened women aged 30 to 65 years also grew over the same period, reaching nearly 1 in 7.
Drawing on 9 cycles of the National Health Interview Survey (NHIS) conducted between 2005 and 2023, researchers found the proportion of women aged 21 to 29 years who reported never being screened for cervical cancer rose from 12.5% (3.5 million women) to 31.9% (6.2 million women), an average annual percentage change (AAPC) of 5.2% (95% CI, 4.3%-7.5%). The increase accelerated sharply after 2010, climbing at an annual rate of 7.9% (95% CI, 6.0%-14.4%) through 2023. Among women aged 30 to 65 years, never-screening rose from 5.3% (4.3 million) to 14.8% (9.2 million), an AAPC of 6.8% (95% CI, 3.1%-12.0%).
Additionally, human papillomavirus (HPV) vaccination uptake among women aged 21 to 29 years climbed from 5.7% in 2008 to 54.0% in 2019 but remains incomplete. The study authors noted that nearly 8 million women in this age group remain unvaccinated, and almost a third of them have also never been screened for cervical cancer.
brewer
don't sniff my butt
Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514
Injection on Abdominal Subcutaneous Fat Reduction
Conclusions CBL-514 injection at multiple doses up to 300 mg with a unit dose of 2.0 mg/cm2 is safe, well-tolerated, and reduced abdominal fat volume and thickness by inducing adipocyte apoptosis. Although other procedures exist to treat abdominal fat, they have limitations and may cause complications. At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics. Level of Evidence: 4
Injection on Abdominal Subcutaneous Fat Reduction
Conclusions CBL-514 injection at multiple doses up to 300 mg with a unit dose of 2.0 mg/cm2 is safe, well-tolerated, and reduced abdominal fat volume and thickness by inducing adipocyte apoptosis. Although other procedures exist to treat abdominal fat, they have limitations and may cause complications. At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics. Level of Evidence: 4